DELFT, Netherlands, Jan. 7, 2025
/PRNewswire/ -- InnoGI Technologies and Bac3Gel are proud to
announce a groundbreaking partnership that grants InnoGI
Technologies exclusive distribution rights for Gut3Beads in the
field of in vitro colonic models.
Gut3Beads, a next generation for in vitro colonic research
developed by Bac3Gel, are innovative hydrogel beads that replicate
the colonic microenvironment, providing a mucin-like substrate to
cultivate diverse intestinal microbiota. This cutting-edge
technology enables researchers to better mimic the native gut
environment, addressing key challenges in gut microbiome
research.
By combining InnoGI's expertise in dynamic gut modeling with
Bac3Gel's advanced technology, the partnership will integrate
Gut3Beads into InnoGI's proprietary SurroGUT™ platform based
on TIM technology, creating a synergistic solution for
gastrointestinal research and drug development.
"Partnering with Bac3Gel is a significant milestone for
InnoGI Technologies, reflecting our commitment to advancing
gastrointestinal research by incorporating innovative tools that
complement the predictive capabilities of our SurroGUT™
platform," says Behzad
Mahdavi, PhD, MBA CEO of InnoGI
Technologies. "Together, we are redefining standards for
simulating the complete human gut microbiome, empowering our
customers to achieve groundbreaking discoveries in drug development
and beyond.".
"Gut3Beads are designed to replicate the key
physical and chemical properties of colonic intestinal mucus,
enabling microbiota to thrive as they would in their native
environment," explains Sebastião van Uden, CEO of Bac3Gel.
"This partnership amplifies our ability to deliver unparalleled
solutions for microbiome research."
A New Standard in Gut Microbiome
Research
Gut3Beads introduce a revolutionary approach
to microbiome research, allowing the study of complex microbial
communities, drug–mucus interactions, and their impact on the
colonic microbiome. Compatibility with SurroGUT™ and TIM technology
offers researchers a state-of-the-art tool to stimulate the colonic
environment and accelerate scientific discovery.
About SurroGUT™ and InnoGI Technologies
InnoGI
Technologies, headquartered in Delft, Netherlands, is an innovative CRO and
technology provider for the pharmaceutical and food industries. Its
SurroGUT™ platform uses advanced in vitro models such as
TIM, mimicking the dynamics of the human gut. TIM replicates
dynamically changing pH profiles, peristalsis, enzyme and digestive
fluid secretions at true-to-life rates. The technology has been
used to evaluate more than 250 active pharmaceutical ingredients in
commercial drug products, and guided clients worldwide with
decision-making at different stages of oral drug development. This
reduces the number of formulation iterations, de-risks clinical
trials, and shortens the time-to-market, as evidenced in more than
260 scientific publications. For more information, visit our
website www.innogitechnologies.com or follow us
on LinkedIn.
About Bac3Gel
Bac3Gel is a biotechnology company that
harnesses the power of the microbiome by replicating the complexity
of native ecosystems and providing microbiota with the conditions
required to thrive. Bac3Gel's product portfolio supports microbiome
mining, high-throughput screening, and boosts the growth of hard to
culture bacteria. Using Bac3Gel's proprietary technology platform,
90% of the microbiome was sustained in vitro while supporting the
growth of 132 previously unidentified bacteria. Bac3Gel offers its
platform to pharma/biotech and CDMOs in collaborative projects. The
company is based in Porto Salvo, Portugal. Further information
at bac3gel.com or follow us
on LinkedIn.
Contact:
Nouschka Verboon
0611256065
388359@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/innogi-technologies-and-bac3gel-forge-partnership-to-revolutionize-gut-microbiome-research-302344377.html
SOURCE InnoGI Technologies
